MRI TWO DISTINCT SUBSETS OF LOW DENSITY

V. Kaneko1, T. Nunokawa2, Y. Taniguchi3, Y. Yamaguchi1, T. Gono, K. Masui4, A. Kawakami1, Y. Kawaguchi1, S. Sato5, M. Kuwana on behalf of JAMI investigators. 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, 3Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Kochi, 4Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, 5Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, 6Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Ibaraki, Japan

Background: Cancer-associated myositis (CAM) is believed to be rarely complicated by interstitial lung disease (ILD), and, thus, detailed clinical characteristics of CAM in patients with polymyositis (PM)/dermatomyositis (DM)-associated ILD are not well known.

Objectives: To clarify the incidence, risk factors, and impact on survival of malignancy in patients with PM/DM-associated ILD, using a large cohort data.

Methods: We used 497 patients with PM/DM-associated ILD enrolled in a multi-centre retrospective cohort of incident cases from 44 institutions across Japan (JAMI). CAM was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic data and clinical characteristics were recorded at the time of diagnosis, and follow-up survival and malignancy data were collected prospectively.

Results: Thirty-two patients with CAM (6.4%) were identified. Patients in the CAM group were older (64.3 vs 55.1 years, p<0.001), had shorter disease duration at onset (4.1 vs 7.0 months, p=0.01), and presented with arthritis less frequently (24.1 vs 48.5%, p=0.01), in comparison with those with non-CAM group. All patients with CAM were older than 40 years, and the proportion of CAM increased along with the age. Patients who were ≥59 years at diagnosis and lacked arthritis were at 12 times higher risk for concomitant malignancy than those without such features (figure 1). Frequencies of autoantibodies, including anti-MDA5, anti-ARS, and anti-TIF1gamma, were not different between the groups. In 19 patients (59%), malignancy was diagnosed within 3 months before or after PM/DM diagnosis. Eleven CAM patients were died, and cause of deaths included ILD in 6 and malignancy in 5. Survival analysis by Kaplan-Meier method demonstrated that CAM patients had a poorer survival than did non-CAM patients (p=0.016).

Conclusions: In patients with PM/DM-associated ILD, older age at diagnosis and lack of arthritis are predictors for concomitant malignancy, which leads to a reduced survival.

Disclosure of Interest: Y. Kaneko Speakers bureau: Astellas, T. Nunokawa: None declared, Y. Taniguchi: None declared, Y. Yamaguchi: None declared, T. Gono: None declared, K. Masui: None declared, A. Kawakami: None declared, Y. Kawaguchi: None declared, S. Sato Grant/research support from: a patent on anti-MDA5 antibody-measuring kit, M. Kuwana Grant/research support from: Astellas, Speakers bureau: Astellas, Japan Blood Products Organisation, Medical and Biological Laboratories


SAT0515

CLINICAL CHARACTERISTICS OF PATIENTS WITH CANCER-ASSOCIATED MYOSITIS COMPLICATED BY INTERSTITIAL LUNG DISEASE

V. Kaneko1, T. Nunokawa2, Y. Taniguchi3, Y. Yamaguchi1, T. Gono, K. Masui4, A. Kawakami1, Y. Kawaguchi1, S. Sato5, M. Kuwana6 on behalf of JAMI investigators. 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, 3Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Kochi, 4Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, 5Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, 6Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Ibaraki, Japan

Background: Cancer-associated myositis (CAM) is believed to be rarely complicated by interstitial lung disease (ILD), and, thus, detailed clinical characteristics of CAM in patients with polymyositis (PM)/dermatomyositis (DM)-associated ILD are not well known.

Objectives: To clarify the incidence, risk factors, and impact on survival of malignancy in patients with PM/DM-associated ILD, using a large cohort data.

Methods: We used 497 patients with PM/DM-associated ILD enrolled in a multi-centre retrospective cohort of incident cases from 44 institutions across Japan (JAMI). CAM was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic data and clinical characteristics were recorded at the time of diagnosis, and follow-up survival and malignancy data were collected prospectively.

Results: Thirty-two patients with CAM (6.4%) were identified. Patients in the CAM group were older (64.3 vs 55.1 years, p<0.001), had shorter disease duration at onset (4.1 vs 7.0 months, p=0.01), and presented with arthritis less frequently (24.1 vs 48.5%, p=0.01), in comparison with those with non-CAM group. All patients with CAM were older than 40 years, and the proportion of CAM increased along with the age. Patients who were ≥59 years at diagnosis and lacked arthritis were at 12 times higher risk for concomitant malignancy than those without such features (figure 1). Frequencies of autoantibodies, including anti-MDA5, anti-ARS, and anti-TIF1gamma, were not different between the groups. In 19 patients (59%), malignancy was diagnosed within 3 months before or after PM/DM diagnosis. Eleven CAM patients were died, and cause of deaths included ILD in 6 and malignancy in 5. Survival analysis by Kaplan-Meier method demonstrated that CAM patients had a poorer survival than did non-CAM patients (p=0.016).

Conclusions: In patients with PM/DM-associated ILD, older age at diagnosis and lack of arthritis are predictors for concomitant malignancy, which leads to a reduced survival.

Disclosure of Interest: Y. Kaneko Speakers bureau: Astellas, T. Nunokawa: None declared, Y. Taniguchi: None declared, Y. Yamaguchi: None declared, T. Gono: None declared, K. Masui: None declared, A. Kawakami: None declared, Y. Kawaguchi: None declared, S. Sato Grant/research support from: a patent on anti-MDA5 antibody-measuring kit, M. Kuwana Grant/research support from: Astellas, Speakers bureau: Astellas, Japan Blood Products Organisation, Medical and Biological Laboratories


SAT0516

MRI – GUIDED THERAPY FOR SYSTEMIC SCLEROSIS ASSOCIATED MYOSITIS

V. Braun-Moscovici1, D. Militianu2, N. Puchkov2, D. Markovtis1, M. Braun3, A. Nahri1, A. Babil-Gurman1. 1Rheumatology department, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion; 2Department of Medical Imaging, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa; 3Liver Institute, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel

Background: Muscle involvement in systemic sclerosis (SSc) has a significant impact on morbidity, functional capacity, and mortality. The muscle histopathology is heterogeneous including inflammatory and fibrotic changes. Currently there are no satisfactory means to diagnose inflammatory myopathy in SSc pts with normal creatine kinase (CK) and to assess the response to therapy.

Objectives: Our aim was to evaluate whether muscle magnetic resonance imaging (MRI) might be a tool to diagnose inflammatory myopathy in SSc pts (patients) and to assess the effect of muscle oriented- immunomodulatory therapy.

Methods: We retrospectively analysed the clinical data of 290 consecutive SSc pts seen at our centre between the years 2012–2017. Our cohort is part of the EUSTAR registry (centre 042). Pts with muscle weakness as defined by the Medsger muscle severity score of ≥1 at least at one MRI study were included. Clinical data analysis included SSc subtype, disease duration, modified Rodnan skin score (mRSS), Medsger muscle severity score, CK, autoantibody profile, MRI and immunomodulatory treatment.

Results: 53 pts with muscle weakness answered the criteria of Medsger muscle severity score of ≥1 and normal CK and for assessment of treatment efficacy.

Conclusions: MRI might serve as a non-invasive tool for diagnosis of inflammatory myopathy in SSc pts with early disease, Medsger muscle severity score of ≥1 and normal CK and for assessment of treatment efficacy.

Disclosure of Interest: None declared


SAT0517

TWO DISTINCT SUBSETS OF LOW DENSITY GRANULOCYTES IN ANCA ASSOCIATED VASCULITIS

A. Endo, Y. Komagata, K. Yamagishi, N. Ikegaya, K. Fukuoka, M. Karube, Y. Arimi, S. Kandori. Division of Nephrology and Rheumatology, First Department of Internal Medicine, Kyorin University School of Medicine, Japan

Background: Low density granulocyte (LDG), a proinflammatory population of neutrophils, was first described in systemic lupus erythematosus (SLE) and has...